Last reviewed · How we verify
NCT05712746
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
trial testing Samtasu for I.V. infusion in Heart Failure in 1,600 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | Otsuka Pharmaceutical Co., Ltd. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,600 |
| Start date | 3 March 2023 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Samtasu for I.V. infusion — full drug profile →
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Otsuka Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05712746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Otsuka Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
- NCT06875986 — REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapi · recruiting
- NCT06036108 — Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia · Phase 1 · completed
- NCT05687071 — A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia · Phase 3 · completed
- NCT05683340 — A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05712746 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Otsuka Pharmaceutical Co., Ltd.
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05712746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing